drugset / Trial / NCT03978611
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) of relatlimab in combination with ipilimumab.
Timeline
- Start
- 2021-12-09
- Primary completion
- 2023-07-26
- Completion
- 2023-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Relatlimab | Monoclonal antibody | — | — |